Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.988
Peer-review started: December 31, 2023
First decision: January 17, 2024
Revised: January 26, 2024
Accepted: March 11, 2024
Article in press: March 11, 2024
Published online: May 15, 2024
Processing time: 131 Days and 6.4 Hours
Visceral obesity is increasingly prevalent among adolescents and young adults and is commonly recognized as a risk factor for type 2 diabetes. Estrogen [17β-estradiol (E2)] is known to offer protection against obesity via diverse me-chanisms, while its specific effects on visceral adipose tissue (VAT) remain to be fully elucidated.
To investigate the impact of E2 on the gene expression profile within VAT of a mouse model of prediabetes.
Metabolic parameters were collected, encompassing body weight, weights of visceral and subcutaneous adipose tissues (VAT and SAT), random blood glucose levels, glucose tolerance, insulin tolerance, and overall body composition. The gene expression profiles of VAT were quantified utilizing the Whole Mouse Genome Oligo Microarray and subsequently analyzed through Agilent Feature Extraction software. Functional and pathway analyses were conducted employing Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses, respectively.
Feeding a high-fat diet (HFD) moderately increased the weights of both VAT and SAT, but this increase was mitigated by the protective effect of endogenous E2. Conversely, ovariectomy (OVX) led to a significant increase in VAT weight and the VAT/SAT weight ratio, and this increase was also reversed with E2 treatment. Notably, OVX diminished the expression of genes involved in lipid metabolism compared to HFD feeding alone, signaling a widespread reduction in lipid metabolic activity, which was completely counteracted by E2 administration. This study provides a comprehensive insight into E2's local and direct protective effects against visceral adiposity in VAT at the gene level.
In conclusion, the present study demonstrated that the HFD-induced over-nutritional challenge disrupted the gene expression profile of visceral fat, leading to a universally decreased lipid metabolic status in E2 deficient mice. E2 treatment effectively reversed this condition, shedding light on the mechanistic role and therapeutic potential of E2 in combating visceral obesity.
Core Tip: It is widely accepted that adipocyte hypertrophy arises from an increase in lipogenesis and/or a reduction in lipolysis. Our findings reveal that despite the presence of adipocyte hypertrophy and visceral adiposity, the expression of genes related to both fatty acid biosynthesis and oxidation in visceral adipose tissue was significantly reduced following ovariectomy (OVX) in mice fed a high-fat diet, suggesting a comprehensive decline in metabolic activity. Remarkably, estrogen treatment fully reversed the disrupted expression patterns of lipid metabolic genes in OVX mice, correcting their disordered metabolic phenotype. This study unveils a novel mechanism underlying visceral adiposity and highlights estrogen's protective role against visceral obesity.